|
TARA | Protara Therapeutics, Inc. |
|
|
TARA | Protara Therapeutics, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 2.02 |
| Leverage | 8.54% |
| Market Cap | $ 65.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -52.7m |
| Margin | -768.80% |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare diseases. The company is headquartered in New York, New York.